{"id":175,"date":"2024-11-19T10:00:00","date_gmt":"2024-11-19T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=175"},"modified":"2025-09-03T03:39:10","modified_gmt":"2025-09-03T03:39:10","slug":"china-bd-2024-velavigo-and-avenzo-enters-a-800-million-usd-license-on-nectin4-trop2-bsadc-program","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/175.html","title":{"rendered":"[China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4\/TROP2 BsADC Program"},"content":{"rendered":"\n<p>Announced Date: 2024-11-18 (November 18, 2024)<\/p>\n\n\n\n<p>Asset Name: <\/p>\n\n\n\n<p>Licensor: VelaVigo Bio (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Avenzo Therapeutics (USA)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: BsADC (Bispecific Antibody-Drug Conjugate)<\/p>\n\n\n\n<p>Asset Target: IGF-1R\/TSHR Nectin4\/TROP2<\/p>\n\n\n\n<p>Current Stage: pre-IND<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>VelaVigo has granted Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize\u00a0a potential first-in-class Nectin4\/TROP2 bispecific\u00a0ADC\u00a0globally (excluding Greater China).<\/p>\n\n\n\n<p> VelaVigo will maintain rights for Greater China and plans to collaborate with Avenzo in global development.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>VelaVigo will receive:<\/p>\n\n\n\n<p>Upfront fee and potential near-term milestones upon option exercise by Avenzo of up to $50 million. <\/p>\n\n\n\n<p>In addition, VelaVigo is eligible to receive future potential development, regulatory, and commercial milestone payments of up to approximately $750 million in total, as well as tiered royalties on sales in Avenzo&#8217;s territory.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4\/TROP2 Bispecific Antibody-Drug Conjugate<\/p>\n\n\n\n<p><a href=\"https:\/\/www.velavigo.com\/cfnews\/45EN.html\">https:\/\/www.velavigo.com\/cfnews\/45EN.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-11-18 (November 18, 2024) Asset Name: Licensor: VelaVigo Bio (China) Licensee (Buyer): Avenzo Therapeutics &hellip; <a title=\"[China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4\/TROP2 BsADC Program\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/175.html\"><span class=\"screen-reader-text\">[China BD 2024] VelaVigo and Avenzo Enters a 800 million USD License on Nectin4\/TROP2 BsADC Program<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-175","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=175"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/175\/revisions"}],"predecessor-version":[{"id":176,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/175\/revisions\/176"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}